Annie joined Omega Funds in 2015. She focuses on private company investing, particularly in the areas of autoimmune and inflammatory diseases and technology platforms. Annie also manages relationships with academic institutions, including Omega’s strategic relationship with MIT.
Prior to joining Omega, she spent three years at MIT’s Technology Licensing Office as a licensing associate and associate licensing officer, where she managed a portfolio of drug delivery and biotechnology inventions. Annie also worked as an independent consultant for Nelsen Biomedical, where she performed market analyses and advised clients on partnering and market entry strategies. Annie earned her PhD in Biomedical Engineering from the University of Michigan and a BS in Biomedical Engineering from the University of Virginia.